RESUMO
Objective:To investigate the clinical efficacy of vascular rehabilitation capsules and calcium dobesilate on non-proliferative diabetic retinopathy and its effect on inflammatory factors.Methods:A total of 80 patients with type 2 diabetes and non-proliferative retinopathy diagnosed in the endocrinology department of First People′s Hospital of Huaihua were randomly divided into the control group ( n=40 cases, 72 eyes) and the observation group ( n=40 cases, 76 eyes). The two groups were given conventional basic treatment. The control group was given calcium dobesilate, and the observation group was added with the combination of vascular rehabilitation capsules and treatment for 24 weeks. After treatment, the clinical therapeutic effects of the two groups were evaluated, and the levels of inflammatory factors interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were analyzed before and after treatment. The occurrence of adverse reactions was monitored during treatment. Results:The total effective rate of the observation group was higher than that of the control group (92.5% vs 75.0%, χ 2=4.501, P<0.05). There was no significant difference in the levels of IL-6 and hs-CRP in the two groups of patients before treatment [(4.41±0.92)pg/ml vs (4.47±0.84)pg/ml, (16.36±4.02)mg/L vs (16.38±3.26)mg/L]; after 12 weeks and 24 weeks of treatment, the levels of IL-6 and hs-CRP in the observation group were significantly lower than those in the control group [12 h: (2.55±0.64)pg/ml vs (2.94±0.59)pg/ml, (12.21±3.48)mg/L vs (14.33±3.04)mg/L; 24 h: (1.93±0.49)pg/ml vs (2.36±0.45)pg/ml, (9.63±3.05)mg/L vs (11.52±2.15)mg/L, all P<0.05]. During the treatment, no serious adverse events occurred in both groups of patients. Conclusions:Vascular rehabilitation capsules combined with calcium dobesilate is an effective treatment for non proliferative diabetic retinopathy. It can improve the clinical efficacy, safety and reduce inflammatory reaction, which is worthy of further clinical application.
RESUMO
Objective:To investigate the effect of edaravone combined with early enteral nutrition on intestinal mucosal barrier function and inflammatory factors in patients with severe craniocerebral trauma.Methods:From January 2017 to December 2018, 80 patients with severe craniocerebral trauma admitted to Lanxi People's Hospital were divided into observation group(40 cases) and control group(40 cases) according to the random digital table method.The control group was given early enteral nutrition treatment, and the observation group was treated with edaravone on the basis of the control group.The course of treatment in both two groups was 4 weeks.Glasgow coma index(GCS), intracranial pressure, NIHSS, intestinal mucosal barrier function and inflammatory factors before and after treatment were compared between the two groups.Results:The GCS score of the observation group[(12.32±1.02)points] was higher than that of the control group[(9.87±1.45)points], while the intracranial pressure[(169.84±10.19)mmH 2O] and NIHSS score[(10.73±1.98)points]of the observation group were lower than those of the control group [(203.24±15.69)mmH 2O and (16.52±3.07)points], the differences were statistically significant( t=8.740, 11.291, 10.024, all P<0.05). The levels of DAO [(0.64±0.12)U/L], endotoxin [(2.54±0.48)U/mL] and D-lactate [(3.64±1.09)μg/L] in the observation group were lower than those in the control group [(1.32±0.30)U/L, (3.64±0.61)U/mL and (5.73±1.18)μg/L] ( t=13.310, 8.963, 8.229, all P<0.05). The levels of IL-6[(27.39±5.64)pg/L], hs-CRP[(10.38±3.24)mg/L] and TNF-α[(7.83±1.79)μg/L] in the observation group were lower than those in the control group [(39.98±9.97)pg/L, (15.64±3.19)mg/L and (13.24±3.21)μg/L] ( t=6.951, 7.317, 9.310, all P<0.05). The good prognosis rate of the observation group(80.00%) was higher than that of the control group(57.00%)(χ 2=4.713, P<0.05). Conclusion:Edaravone combined with early enteral nutrition has good effect on the patients with severe craniocerebral trauma.It can improve the intestinal mucosal barrier function, reduce the inflammatory response and improve the prognosis.
RESUMO
Objective:To investigate the effect of microinvasive craniopuncture scavenging technique(MPST) in the treatment of hypertensive intracerebral hemorrhage, and its influence on the expression of serum matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8) and neuron specific enolase (NSE).Methods:From January 2017 to December 2018, 60 cases with hypertensive cerebral hemorrhage in Lanxi People's Hospital of Zhejiang province were divided into observation group (30 cases) and control group (30 cases) according to the digital table method.The control group was treated with conventional therapy, while the observation group was treated with MPST on the basis of the control group.The therapeutic effects of the two groups were compared, and the changes of Barthel index (BI) score, NIHSS score, perihematoma edema, MMP-9, IL-8 and NSE levels were compared.Results:The total effective rate in the observation group(93.33%) was higher than that in the control group (70.00%) (χ 2=5.455, P<0.05). The BI score[(60.19±5.87)points] of the observation group was higher than that of the control group[(49.83±4.56)points], while the NIHSS score[(7.93±1.42)points] was lower than that of the control group[(12.87±2.10)points]( t=7.634, 10.673, all P<0.05). The amount of edema around hematoma in the observation group [(6.20±1.27)mL] was lower than that in the control group [(9.83±1.76)mL] ( t=9.161, P<0.05). The levels of MMP-9 [(103.24±17.38)μg/L], IL-8 [(137.28±25.46)μg/L] and NSE [(8.98±2.16)μg/L] in the observation group were lower than those in the control group [(168.39±15.42)μg/L, (195.31±39.71)μg/L and (13.13±2.63)μg/L] ( t=15.358, 6.738 and 6.679, all P<0.05). Conclusion:MPST is effective in the treatment of hypertensive intracerebral hemorrhage, and it can reduce the serum levels of MMP-9, IL-8 and NSE.
RESUMO
Objective To compare the curative effect of Epalrestat and mecobalamine .Methods Epalrestat to treat 48 pa-tionts in DPN and mecobalamine to treat 42,measuring blood sugar ,blood pressure, blood fat and body mass index (BMI) prior and post treatment ,and measuring the MCV and SCV of nervus medianus ,nervus peronaeus connunis and nervus tibialis with EMG .Re-sults The symptom of the two sets have all been improved after the treatment ,and the effective power of Epalrestat and mecobalamine is 92.7% and 80.5% respectively.mean while there is improvement in MCV and SCV of nervus medianus ,nervus peronaeus connunis and nervus tibialis,and is more obvious in the set of Epalrestat ( P <0.01).In the whole process of the treat of the two sets ,no one appear to have adverse reactions .Conclusions Epalrestat has significant curative effect with less adverse reactions , and deserves to be spreaded in clinic.